Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer
- PMID: 29208774
- DOI: 10.1158/2159-8290.CD-17-1086
Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer
Abstract
<b/> Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. Cancer Discov; 7(12); 1368-70. ©2017 AACRSee related article by Chaudhuri et al., p. 1394.
©2017 American Association for Cancer Research.
Comment on
-
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24. Cancer Discov. 2017. PMID: 28899864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical